Chunks with this article
Eli Lilly - Antibody injections - a leading candidate for COVID19 Coronavirus cure, treatment

Save to folder

Choose Folders Loading...

Article Public (all visitors)

U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns

CNBC 2020

The ACTIV-3 trial is one of several ongoing trials that are part of an NIH program to accelerate the development of vaccine treatments.

View Original Source

Curated by

FoundryBase

Updated 11 months ago

ACADEMIC RESEARCH HEALTHCARE MEDICINE PHARMACEUTICAL INDUSTRY

Save

Bookmark this resource

Browse more

View all Articles

Conversation

Comments

No comments yet. Be the first to comment!

Transcription

Placed in

Chunks with this Article

1 chunk

Eli Lilly - Antibody injections - a leading candidate for COVID19 Coronavirus cure, treatment Antibody injections, treatment - a leading candidate for COVID19 Coronavirus cure FoundryBase 5 resources

Adjacent discoveries

Related resources

Shared chunks

Resources placed near this one.

Coronavirus: U.S. begins 2 trials testing Eli Lilly's coronavirus antibody drug Article • 2020 • CNBC Appears in 1 shared chunk

Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment Article • 2020 • CNBC Appears in 1 shared chunk

Nature: The race to make COVID antibody therapies cheaper and more potent (Oct. 2020) Article • 2020 • NATURE Appears in 1 shared chunk

As monoclonal antibody Covid-19 treatment arrives, hospitals scramble to solve logistical and ethical challenges Article • 2020 • STAT Appears in 1 shared chunk

Shared categories

Resources with similar topic signals.

FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline Article • 2021 • STAT Shares 4 topic signals

Personalized Skin Cancer Vaccine Shows Promise in New Trial Results Article • 2021 • Gizmodo Shares 4 topic signals

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race Article • 2020 • STAT Shares 4 topic signals

Why Oxford’s positive COVID vaccine results are puzzling scientists Article • 2020 • NATURE Shares 4 topic signals

Oxford University’s COVID-19 vaccine shows high efficacy, and is cheaper to make and easier to store Article • 2020 • TechCrunch Shares 4 topic signals

Moderna: Covid vaccine shows nearly 95% protection Article • 2020 • BBC News Shares 4 topic signals

Dozens of COVID-19 vaccines are in development. Here are the ones to follow - National Geographic Article • 2020 • Science Shares 4 topic signals

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug Article • 2020 • Science | AAAS Shares 4 topic signals

Nature: The race to make COVID antibody therapies cheaper and more potent (Oct. 2020) Article • 2020 • NATURE Shares 4 topic signals

Remdesivir has ‘little or no effect’ in reducing coronavirus deaths, WHO says Article • 2020 • CNBC Shares 4 topic signals

A Kid's Covid Vaccine Isn't Coming Anytime Soon - The New York Times Article • 2020 • NYTIMES Shares 4 topic signals

Synthetic biologists have created a slow-growing version of the coronavirus to give as a vaccine Article • 2020 • MIT Technology Review Shares 4 topic signals

U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns

FoundryBase

Related resources

More from source

Found something worth adding?